Wegovy

Semaglutide, sold under the brand names Ozempic, Wegovy and Rybelsus, is an antidiabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management, developed by Novo Nordisk in 2012.Semaglutide is a GLP-1 receptor agonist, meaning that it mimics the action of the human incretin glucagon-like peptide-1 (GLP-1), thereby increasing insulin secretion and increasing blood sugar disposal and improving glycemic control.

Read more in the app

You Quit Ozempic or Wegovy. What Happens Next?

Patients Hate ‘Forever’ Drugs. Are Ozempic and Wegovy Different?

Patients Hate ‘Forever’ Drugs. Are Ozempic and Wegovy Different?

Ozempic and Wegovy linked to a lower risk of cannabis use disorder

Wegovy Is First Weight-Loss Drug Approved for Heart Diseases

FDA Approves Wegovy For Heart Conditions in Game-Changing Move

Unlocking Your Body’s Natural Weight Loss System That Works Like Wegovy, Ozempic and Mounjaro

Alarm Bells Over Wegovy: Lax Regulation of Weight Loss Drug Ads Poses Serious Health Risks

6 Reasons That It’s Hard to Get Your Wegovy and Other Weight-Loss Prescriptions

Ozempic and Wegovy Users Had Less Risk of Suicidal Thoughts in Large Study

Move Over Wegovy—a Plant-Based Diet May Be a Better Answer for Weight Loss

2024 will see a new weight-loss drug that trumps Wegovy and Ozempic

Ozempic and Wegovy may reduce inflammation by targeting the brain

The weight loss drug Wegovy lowered heart attack risk in a large trial

Weight-loss drug Wegovy can avert heart attacks - will this widen use?

Wegovy Slashes the Risk of Heart Attack and Stroke in a Landmark Trial

F.D.A. Approves New Obesity Drug Tirzepatide That Will Compete With Wegovy

The FDA Approves Weight Loss Drug Zepbound, a Wegovy and Ozempic Rival

Scientists Warn: Popular Weight Loss Medications Like Ozempic and Wegovy Could Be Dangerous for Children

How Much Do Ozempic and Wegovy Cost? Not What You Think.